RBRobin Julian Biellik

Robin Julian Biellik

*This is an algorithmically generated author record based on publicly available information.

Robin Julian Biellik has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Measles–Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations

    by Darin Zehrung, Bruce L. Innis, Auliya A. Suwantika, Mahmoud Ameri, Robin Biellik, James C. Birchall, Alejandro Cravioto, Courtney Jarrahian, Lee Fairlie, James L. Goodson, et al.

    Background: The Measles–Rubella Microarray Patch (MR-MAP) is an important technology that is expected to reduce coverage and equity gaps for measles-containing vaccines (MCVs), reach zero-dose children, and contribute to elimination of measles and rubella. MR-MAPs are anticipated to be easier to deploy programmatically and could be delivered by lesser-trained health workers, thereby increasing immunization coverage. The most advanced MR-MAP has reached clinical proof-of-concept through a Phase I/II trial in the target population of infants and young children. The World Health Organization (WHO) and partners have developed the Phase III clinical trial framework for MR-MAPs presented in this article. Objectives and Methods: The purpose of such framework is to inform the considerations, design and approach for the pivotal clinical trial design, while considering the anticipated data requirements to inform regulatory approval, WHO prequalification, and policy decision. Results: The proposed Phase III trial would compare the immunogenicity and safety of an MR-MAP with MR vaccine delivered subcutaneously in 9- to 10-month-old infants. An analysis of non-inferiority (NI) of immunogenicity would occur six weeks after the first dose. Should regulatory agencies or policy makers require, a proportion of infants could receive a second dose of either the same or alternate MR vaccine presentation six months after the first dose, with those children returning six weeks after the second dose for a descriptive assessment of immunogenicity, and then followed up six months after the second dose for evaluation of safety and immunogenicity. It is anticipated that this proposed pivotal Phase III trial framework would generate the required clinical data for regulatory licensure and WHO prequalification (PQ) of MR-MAPs. However, the trial design would need to be reviewed and confirmed by a national regulatory authority (NRA) that will assess the product for regulatory licensure and the WHO PQ team. Additional research will likely be required to generate data on concomitant vaccine delivery, the safety and immunogenicity of MR-MAPs in other age groups such as children 1–5 years and infants younger than 9 months of age, and the impact of MR-MAPs on coverage and equity. Such studies could be conducted during or after clinical MR-MAP development.


  • Open Access

    The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region

    by Justin R. Ortiz, Joanie Robertson, Jui-Shan Hsu, Stephen L. Yu, Amanda J. Driscoll, Sarah R. Williams, Wilbur H. Chen, Meagan C. Fitzpatrick, Samba Sow, Robin J. Biellik, et al.


  • Open Access

    The operational impact of deploying SARS-CoV-2 vaccines in countries of the WHO African Region

    by Justin R. Ortiz, Joanie Robertson, Jui-Shan Hsu, Stephen L. Yu, Amanda J. Driscoll, Sarah R. Williams, Wilbur H. Chen, Meagan C. Fitzpatrick, Samba Sow, Robin J. Biellik, et al.

    Background: After SARS-CoV-2 vaccines become available, they will be deployed to many countries with limited immunization systems. Methods: We conducted a cold chain capacity assessment of a simulated country in the WHO African Region. We combined region-specific data regarding immunization, population, healthcare workforce, and cold storage capacity (upper and lower range and quartile values for national and subnational levels). We used seasonal influenza vaccines as proxies for SARS-CoV-2 vaccines. We evaluated the increase in vaccine doses to be administered, doses administered per vaccinator, and cold storage volumes for SARS-CoV-2 campaigns targeting risk groups compared to routine immunization baselines. Findings: Compared to routine immunization, a SARS-CoV-2 vaccination campaign would increase monthly doses administered when targeting risk groups: ≥65 years (29.9%), chronic diseases patients (101.5%), and healthcare workers (1.2%). SARS-CoV-2 vaccination campaigns would increase doses administered per vaccinator for risk groups: ≥65 years (32.5%), chronic diseases patients (110.4%), or healthcare workers (1.4%). Routine vaccine volumes already exceed national level storage capacity for at least 75% of African Region countries, but subnational levels would have sufficient storage capacity for SARS-CoV-2 vaccines in all but the lower 25% of African Region countries. Interpretation: SARS-CoV-2 vaccination campaigns would substantially increase doses per vaccinator and cold chain capacity requirements over routine immunization baselines. Pandemic vaccination campaigns would add volume to national level stores already at their limits, but substantial capacity exists at subnational levels for SARS-CoV-2 vaccines. Immediate attention to strengthening delivery systems is essential to support pandemic vaccine responses in the African Region. Funding: None


  • Open Access

    Strengthening routine immunization through measles-rubella elimination

    by Robin J. Biellik, Walter A. Orenstein


  • Open Access

    The new World Health Organization recommendation on the 2-dose measles vaccine schedule and the way forward in African region

    by Robin Julian Biellik, Robert Davis

    The new W.H.O. recommendation, which drops the coverage criterion for adoption of the 2-dose measles vaccine schedule, makes some African countries eligible for the 2-dose schedule which were previously ineligible. We look at the implications of the new recommendation for Ethiopia and Nigeria, the two largest African countries which are eligible under the new recommendation.


  • Open Access

    Slow Progress In Finalizing Measles And Rubella Elimination In The European Region

    by Robin Biellik, Iria Davidkin, Susanna Esposito, Andrey Lobanov, Mira Kojouharova, Günter Pfaff, José Ignacio Santos, John Simpson, Myriam Ben Mamou, Robb Butler, et al.

    All countries in the World Health Organization European Region committed to eliminating endemic transmission of measles and rubella by 2015, and disease incidence has decreased dramatically. However, there was little progress between 2012 and 2013, and the goal will likely not be achieved on time. Genuine political commitment, increased technical capacity, and greater public awareness are urgently needed, especially in Western Europe.


  • Open Access

    Supporting countries in establishing and strengthening NITAGs: Lessons learned from 5 years of the SIVAC initiative

    by Alex Adjagba, Kamel Senouci, Robin Biellik, Nyambat Batmunkh, Pape Coumba Faye, Antoine Durupt, Bradford D. Gessner, Alfred da Silva